Daily Archives: January 18, 2018

The recurrent and debilitating nature of Inflammatory Bowel Disease (IBD) makes affected patients ideal candidates to assess the therapeutic potential of a digital intervention for long-term patient management. HealthPROMISE is an innovative software p… Continue reading →

Anti-cytotoxic-T-lymphocyte associated antigen-4 (anti-CTLA4), and anti-programmed cell death 1 (anti-PD1) immunotherapies are considered first-line treatments for advanced melanoma. However, the use of these agents is limited by gastrointestinal toxic… Continue reading →

An expanding range of therapeutics have been approved or are under development for IBD. However, objective readouts of treatment efficacy are still lacking, often relying on partially subjective clinical endpoints (CDAI). High-dimensional mass cytometr… Continue reading →

Seronegative spondyloarthopathies in inflammatory bowel disease (IBD) include ankylosing spondylitis and spondylitis associated with IBD and represent a spectrum of inflammatory axial arthropathies (IAA). Continue reading →

TNF-inhibitor (TNF) therapy was approved for use in moderately active ulcerative colitis (UC) in 2005. We were interested in studying to what extent newly approved biologics with a different mechanism of action (MOA) had on utilization. Continue reading →

Immune dysregulation is thought to be a contributing factor to the development of microscopic colitis (MC), which encompasses lymphocytic and collagenous colitis. MC pattern has been observed in colitis resulting from immunotherapy, newer agents that w… Continue reading →

Inflammatory Bowel Diseases (IBD) are known to be associated with intra- and extra-intestinal symptoms such as pelvic floor dysfunctions (PFD), fatigue, and arthopathies1. The extent to which these symptoms persist and their effects on patient quality … Continue reading →

Inflammatory bowel diseases (IBD) include two major forms of chronic intestinal disorders: Crohn’s disease (CD) and ulcerative colitis (UC). A single gold standard for the diagnosis of CD is not available. Serum protein profiling of CD was investigat… Continue reading →

Immuno-checkpoint inhibitors (ICI) are becoming an integral part of advanced cancer treatment. ICI-induced colitis (ICI-C) is one of the most common adverse events that is usually treated with steroids, infliximab or vedolizumab. All these agents are i… Continue reading →

Gut microbiota is shown to be linked with response to steroids in some diseases (bronchial asthma). Sufficient changes of intestinal microbiota composition in inflammatory bowel diseases (IBD) patients were shown by numerous investigators. Continue reading →